Navitoclax binds to BCL-2, BCL-xL, and BCL-w in vitro, while BCL-2 plays a key role in vivo and high expression of BCL-2 exhibited sensitivity to Navitoclax in human non-Hodgkin lymphomas instead of BCL-xL or BCL-w [51]. Here, BCL2 is linked to non-Hodgkin lymphoma.